BioLife Solutions Reports Loss-to-Profit Swing on All Three Profitability Lines for Both the Quarter and Six-Month Year-to-Date Period

Bottom line

BIOLIFE SOLUTIONS INC (BLFS) filed a Form 10-Q covering the three-month reporting period the three months ended June 30, 2026 and the six-month year-to-date period the six months ended June 30, 2026, with the prior-year comparatives the three months ended June 30, 2025 and the six months ended June 30, 2025. The filing was submitted under CIK 0000834365 and accession 0001628280-26-054355 for fiscal period period-ended-2026-06-30. This is the lead section of a seven-part English Lizely Finance Earnings Analysis, so the scope here is strictly identity, source perimeter, and headline financial outcome — narrative discussion, segment color, and balance-sheet walk-throughs are deferred to later sections.

The headline outcome is a swing from loss to profit on every reported profitability line the catalog supports. For the three-month reporting period the three months ended June 30, 2026, Earnings Per Share, Diluted moved from a loss of -$0.33 per diluted share USD/SHARES in the three months ended June 30, 2025 to a profit of $0.91 per diluted share USD/SHARES. Net Income (Loss) Attributable to Parent likewise moved from a loss of -$15,838,000 USD in the three months ended June 30, 2025 to a profit of $45,104,000 USD. Operating Income (Loss) followed the same shape, from a loss of -$16,126,000 USD to a profit of $1,696,000 USD.

For the six-month year-to-date period the six months ended June 30, 2026, the same loss-to-profit transition is reported across each line. Earnings Per Share, Diluted moved from a loss of -$0.34 per diluted share USD/SHARES in the six months ended June 30, 2025 to a profit of $0.94 per diluted share USD/SHARES. Net Income (Loss) Attributable to Parent moved from a loss of -$16,286,000 USD to a profit of $46,290,000 USD. Operating Income (Loss) moved from a loss of -$16,624,000 USD to a profit of $1,725,000 USD. Each comparison is authorized as a higher-than-the-prior-period direction with an authorized transition from loss to profit, and no reader-facing prose here derives a separate magnitude, margin, or growth percentage from those values.

The source perimeter for this filing spans several distinct corporate developments that the rest of the analysis will lean on. The company is a life-sciences supplier of biopreservation media, cryogenic vials, automated cell-processing equipment, and automated thawing devices used by cell and gene therapy customers. The narrative also references a pending acquisition by Repligen Corporation under a Merger Agreement described in Note 18, a divestiture of the SAVSU business that is presented as a discontinued operation under Note 3, and the PanTHERA acquisition described in Note 2. Because SAVSU is presented as discontinued operations for all applicable periods, amounts and percentages reflect only the continuing operations of the Company unless otherwise noted. The filing evidence does not attribute this change to any single cause.

Two investor-facing adjacent reads are worth flagging for context only: a similar quarterly profit-return story for a different issuer is documented in Microchip Technology Posts Higher Revenue, Operating Income, and a Return to Profitability Versus Prior-Year Quarter, and the WSFS Financial Corporation interim report in WSFS Financial Corporation Posts Higher Year-Over-Year Diluted EPS and Net Income for Both the Quarter and the Six-Month Year-to-Date Period shows the same six-month and three-month transition that this BioLife filing reports.

This section deliberately stays narrow: it confirms the issuer, the form, the two reporting periods and their comparatives, and the unanimous loss-to-profit transition on the three reported profitability lines, without yet entering segment color, cash-flow commentary, or balance-sheet interpretation. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

Financial performance

- For the three-month reporting period, Earnings Per Share, Diluted moved from a loss in the prior-year comparative to a profit in the current quarter, an authorized loss-to-profit transition and an authorized increase. 33 per diluted share USD/SHARES for the prior-year comparative three-month period. - For the six-month year-to-date period, Earnings Per Share, Diluted likewise swung from a loss to a profit, an authorized loss-to-profit transition.

34 per diluted share USD/SHARES for the prior-year comparative six-month window. - Net Income (Loss) Attributable to Parent shows the same pattern at both horizons. The current quarter is a profit of $45,104,000 USD, against a loss of -$15,838,000 USD in the prior-year quarter, an authorized loss-to-profit transition.

Year-to-date, Net Income (Loss) Attributable to Parent is a profit of $46,290,000 USD for the six-month period, versus a loss of -$16,286,000 USD in the prior-year comparative six-month window, also an authorized loss-to-profit transition. - Operating Income (Loss) tracks the same shape. The current three-month reporting period shows a profit of $1,696,000 USD, against a loss of -$16,126,000 USD in the prior-year comparative quarter, an authorized loss-to-profit transition.

For the six-month year-to-date period, Operating Income (Loss) is a profit of $1,725,000 USD versus a loss of -$16,624,000 USD in the prior-year comparative period, again an authorized loss-to-profit transition. - The filing evidence does not attribute this change to any single cause. - The accounting backdrop framing these numbers is itself shifting.

Per Note 3, the Company is presenting SAVSU as a discontinued operation for all applicable periods presented within the Unaudited Condensed Consolidated Balance Sheets and Unaudited Condensed Consolidated Statements of Operations, while the statements of comprehensive income, shareholders' equity, and cash flows are presented on a consolidated basis covering both continuing and discontinued operations. The same note instructs that all amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted.

Per Note 2, the Company completed the PanTHERA Transaction during the quarter, acquiring the remaining shares of PanTHERA CryoSolutions Inc. not previously owned. Management describes PanTHERA as holding a patented cryopreservation technology intended, upon achievement of commercial viability, to enhance the Company's core capabilities in biopreservation and within the CGT market.

- Item 8 also discloses a change in inventory valuation method. Use of estimates is reiterated, with management flagging that significant estimates and assumptions affect items including valuation of market-based stock awards, fair value of marketable debt securities, recoverability of long-lived assets, intangibles and goodwill, net realizable value of inventory, and the provision for income taxes, with actual results that could differ materially. S.

dollars, and the Company states that its sales are not generally impacted by foreign currency exchange rates. - For readers benchmarking income-statement lines against historical filings, the authorized year-over-year relations above are the only directional comparisons the filing evidence supports. Quarter-over-quarter direction is not part of the authorized comparison set for these metrics, so any read on sequential movement against the prior quarter is not stated here.

Management does not provide forward guidance in this filing. The filing evidence contains no peer or industry comparison. - The broader income-statement pattern of a swing from loss to profit at both horizons is consistent with the kind of clean directional reversal often highlighted in WSFS Financial Corporation Posts Higher Year-Over-Year Diluted EPS and Net Income for Both the Quarter and the Six-Month Year-to-Date Period, though the underlying businesses and drivers are not comparable.

Operating drivers and segments

The Company views its operations and manages its business as one reportable segment and one reporting unit, per the segment disclosure in Note 16: Segment, customer, and geographic information. As a result, this filing does not break out revenue, cost of revenue, or operating margin by distinct operating segments. Operating performance is therefore presented in aggregate, and any inference about segment-level drivers from this filing is not supportable. Reported Operating Income (Loss) for the three-month period is $1,696,000 USD, compared with -$16,126,000 USD in the prior-year quarter; for the six-month year-to-date period it is $1,725,000 USD versus -$16,624,000 USD in the prior-year comparative period. Both the quarter and the half-year show a transition from a loss to a profit, and the half-year also shows a year-over-year increase in operating income.

Management describes the Company as a life sciences business developing, manufacturing, and marketing bioproduction products and services for the cell and gene therapy industry, with a product portfolio that includes proprietary biopreservation media, human platelet lysate media, cryogenic vials, automated cell-processing fill machines, and automated thawing devices. The CryoStor freeze media and HypoThermosol hypothermic storage media lines are positioned for the regenerative medicine market, while the Sexton product line addresses cell expansion and closed-system fill and retrieval, and the ThawSTAR product line covers automated thawing of cell and gene therapies. Management also discloses that, in October of the reporting year, the Company entered into the SAVSU Purchase Agreement with Peli BioThermal LLC to sell all of the issued and outstanding membership interests of SAVSU Cleo Technologies, LLC, presented as a discontinued operation in the accompanying financial statements; the cited acquisition of PanTHERA CryoSolutions Inc. is referenced in Note 2: Acquisition, and the subsequent Repligen merger agreement entered into in July is referenced in Note 18: Subsequent events. The filing evidence does not attribute this change to any single cause.

Independent analysis: Because the Company reports a single segment, no segment-level margin walk, mix shift, or operating-driver breakdown is available from the filing evidence; segment-level driver commentary is therefore not stated. The reported transition from a prior-year loss to a current profit in both the three-month and six-month periods is an authorized comparison under this filing's evidence, as is the authorized year-over-year increase in operating income for the six-month period. The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. The Company has not provided a peer or industry benchmark in this filing, and discontinued-operations presentation for SAVSU limits the comparability of prior-period figures for that business across the periods shown. Risk-factor and controls disclosures appear under Item 1A and Item 4, and subsequent events under Note 18, each of which is referenced rather than re-narrated here.

Cash flow and capital

Reported facts

- The operating-activities line for the six-month year-to-date window was positive cash provided, per the cash-flow statement for BIOLIFE SOLUTIONS INC in the 10-Q for period-ended-2026-06-30 filed under accession 0001628280-26-054355. The prior-year comparative for the same six-month stretch was also a positive operating cash figure. Management has flagged, in a separate filing year, that "the global business environment continues to be impacted by cost pressure, volatility in global trade policies through significant increases in tariffs, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors," language that was carried forward in the cited note context. - The investing-activities line for the current six-month period was a cash use, per the statement, against a cash use in the prior-year comparative window. Payments to acquire property, plant, and equipment were an outflow in both the current and prior-year six-month periods; the authorized direction between the two is a decrease. - The financing-activities line for the current six-month window was a cash use, per the statement, against a cash use in the prior-year comparative window, with the authorized direction between the two being a decrease. - At the the balance sheet date of June 30, 2026 balance sheet date, cash and cash equivalents stood at the reported carrying value per the catalog; accounts receivable was the balance after the allowance for credit loss; and accounts payable was on the current-liability side, all per the cited note context. - The Company views its operations and manages its business as a single reportable segment, per the cited note on segment, customer, and geographic information.

Management explanations

- Management stated that "based on the Company's current expectations with respect to its future revenue and expenses, the Company believes that its current level of cash, cash equivalents, and other liquid assets will be sufficient to meet its liquidity needs for at least the next twelve months from the date of the filing of this Form 10-Q," language that anchors the working-capital and liquidity framing of this section. - Management described an inventory-costing change to a uniform weighted-average method from the start of the recent quarter, with the cited note stating the change "did not have a material effect on inventories, cost of revenue, or net income for all periods presented; therefore, prior comparative financial statements have not been restated." - Management discussed milestone development payments tied to the PanTHERA development and license agreement, under which "the Company made milestone development payments in exchange for exclusive, perpetual, and worldwide marketing and distribution rights to the technology for use in CGT applications," per the cited note. - Management noted that recent accounting pronouncements, including the ASU on environmental credits and the standard addressing paid-in-kind dividends on equity-classified preferred stock, "are not expected to have a material impact on its Consolidated Financial Statements and related disclosures."

Analyst inference

- Operating cash remained positive year over year on a six-month basis, which is consistent with the profit-versus-loss transition shown earlier in the filing for net income and operating income. - Investing cash outflows continued into the current window, with payments to acquire property, plant, and equipment lower than the prior-year comparative. - Financing cash outflows widened, consistent with the authorized decrease direction.

Counter-evidence

- The cited note context flags that "the global business environment continues to be impacted by cost pressure, volatility in global trade policies through significant increases in tariffs, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors," a risk overlay that cuts against a clean read on liquidity durability.

Unknowns

- The filing evidence does not attribute the financing or operating cash movements to any single cause. The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison for these cash and balance-sheet lines. The filing evidence contains no peer or industry comparison.

Peer and historical context

BIOLIFE SOLUTIONS INC (BLFS) files under 10-Q for period-ended-2026-06-30 (accession 0001628280-26-054355, CIK 0000834365), and this section reads the comparative columns the filing lays out side by side: the three-month reporting period the three months ended June 30, 2026 against the prior-year quarter the three months ended June 30, 2025, and the six-month year-to-date period the six months ended June 30, 2026 against the prior-year six-month period the six months ended June 30, 2025.

On the operating line, Operating Income (Loss) for the quarter moved from a loss in the three months ended June 30, 2025 to a profit in the three months ended June 30, 2026, and the same loss-to-profit flip repeats for the six-month view, where the half-year result moved from a loss in the six months ended June 30, 2025 to a profit in the six months ended June 30, 2026. The corresponding bottom-line measure, Net Income (Loss) Attributable to Parent, follows the identical pattern on both windows: a loss in the three months ended June 30, 2025 becomes a profit in the three months ended June 30, 2026, and a loss in the six months ended June 30, 2025 becomes a profit in the six months ended June 30, 2026. Operating Income (Loss) therefore moved in the same direction as Net Income (Loss) Attributable to Parent across both windows, which keeps the operating-versus-net relationship internally consistent across the comparative columns. The filing evidence does not attribute this change to any single cause.

The cash-flow statement, however, does not mirror that improvement. Net Cash Provided by (Used in) Operating Activities remained positive on both halves of the comparison, but the six-month year-to-date figure in the six months ended June 30, 2026 came in lower than the prior-year comparative for the six months ended June 30, 2025. That divergence — profitability strengthening on the income statement while operating cash flow weakens on the year-to-date cash flow statement — is the most notable mismatch between the two halves of the report, and the filing does not reconcile the two inside the quoted evidence. The filing evidence does not attribute this change to any single cause.

For outside context, the filing itself flags one peer-oriented change in accounting policy. The thaw-inventory switch described in the source narrative moves all inventories to a weighted average costing method and the Company explicitly states that the change "improves comparability with peers." The cited reference for that discussion is Item 8, and the change in inventory valuation method is discussed there. Discontinued-operations context that touches the comparability of the prior periods sits in the cited note Note 3, while the acquisition note Note 2 describes how SAVSU is being presented in this filing. None of these notes, however, contain a like-for-like peer benchmark — there is no named peer, no industry index, and no third-party comparison table inside the filing evidence. The filing evidence contains no peer or industry comparison. Readers looking for a cross-company comparison should therefore treat the prior-year columns in this filing as the only historical benchmark available, and look elsewhere — for example, the comparable interim pattern described in WSFS Financial Corporation Posts Higher Year-Over-Year Diluted EPS and Net Income for Both the Quarter and the Six-Month Year-to-Date Period — if they want a read on how a peer year-over-year profit swing looks against a different issuer.

Scenario analysis

- In the base scenario, BIOLIFE SOLUTIONS INC sustains the swing to profitability recorded in this 10-Q for period-ended-2026-06-30. Net Income (Loss) Attributable to Parent of $45,104,000 for the three months ended June 30, 2026 and $46,290,000 for the six months ended June 30, 2026 hold steady, with margins anchored by recurring biopreservation demand and the cell-processing mix highlighted by management when discussing the SAVSU Divestiture. - Operating Income (Loss) for the six months ended June 30, 2026 and the three months ended June 30, 2026 stays positive at a level consistent with the year-to-date and quarterly figures presented, and Earnings Per Share, Diluted remains in profit territory on both a quarterly and a year-to-date basis, in line with the authorized year-over-year transitions recorded by the filing.

- The upside case layers on the PanTHERA Transaction, where BIOLIFE SOLUTIONS INC acquired ownership of the IRI GEN cryopreservation technology and secured exclusive, perpetual, worldwide marketing and distribution rights for CGT applications, with up to the cited note earnout over a three-year period if revenue and operational milestones are met. - Achievement of those milestones would broaden the biopreservation franchise inside the CGT market beyond the current recurring base, supporting a higher Operating Income (Loss) for the three months ended June 30, 2026 relative to the figure presented and reinforcing the year-to-date Operating Income (Loss) profitability for the six months ended June 30, 2026, while Earnings Per Share, Diluted on both a quarterly and a year-to-date basis extends further into positive territory.

- The downside case focuses on the PanTHERA earnout mechanics. As of the cited month, management judged the probability that PanTHERA Sellers would hit the outlined revenue and operational targets to be remote, so no earnout consideration has been recognized to date; an adverse reassessment that forces recognition of the contingent obligation would weigh on net results and could compress Net Income (Loss) Attributable to Parent for the three months ended June 30, 2026 and the six months ended June 30, 2026 away from the levels presented. - Additional downside pressure can arise from the IRI GEN cryopreservation technology itself, which was still under development at acquisition and was immediately expensed under the cited accounting guidance; further development charges or write-downs before commercial viability would erode the Operating Income (Loss) profitability now visible for both the three months ended June 30, 2026 and the six months ended June 30, 2026, and could reverse the Earnings Per Share, Diluted transition from loss to profit on a quarterly and year-to-date basis.

Unknowns and counter-evidence: - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The contingent PanTHERA earnout, the embedded change in control protective provision, and the IPR&D treatment of the acquired cryopreservation technology together create an asymmetric risk profile; no segment-level breakout of these items is provided in the cited note, and The filing evidence does not disclose segment-level detail for this dimension..

Investors weighing the path from the reported profit of $46,290,000 for the six months ended June 30, 2026 against the prior-year loss of -$16,286,000 for the six months ended June 30, 2025, or the swing from -$15,838,000 for the three months ended June 30, 2025 to $45,104,000 for the three months ended June 30, 2026, can frame those anchors alongside a WSFS Financial Corporation Posts Higher Year-Over-Year Diluted EPS and Net Income for Both the Quarter and the Six-Month Year-to-Date Period comparison and a Calculate ROI for an Investment: The Core Formula framework before sizing positions.

Risks and what to watch

- The headline swing across both windows is the most important signal to track in BIOLIFE SOLUTIONS INC's next interim filing, and it cuts in opposite directions depending on which line you read. For the three-month reporting period, Net Income (Loss) Attributable to Parent moves from a loss of -$15,838,000 in the three months ended June 30, 2025 to a profit of $45,104,000 in the three months ended June 30, 2026, a loss-to-profit transition that also shows up in diluted earnings per share for the same period. For the six-month year-to-date comparison, the same line moves from a loss of -$16,286,000 in the six months ended June 30, 2025 to a profit of $46,290,000 in the six months ended June 30, 2026, again a loss-to-profit transition, and the diluted earnings per share move in the same direction for the half-year window. Operating Income (Loss) follows the same pattern, a loss-to-profit transition for both the quarter and the half-year when set against the prior-year comparatives.

- Reported facts. The only profit-and-loss items the catalog authorises for this section are the four net-income observations above; no other income-statement line is supplied with a key, and every other directional claim in the machine-authorised list relates to balance-sheet or cash-flow lines rather than earnings, so they are not the centrepiece of a risks write-up.

- Management explanations. Management's stated rationale for discontinuing SAVSU is that the divestiture lets the company optimise its product portfolio toward recurring higher-margin revenue streams tied to its cell processing products. Management has separately determined that the probability of the PanTHERA Sellers achieving the revenue and operational earnout targets is remote, and on that basis has recognised no earnout consideration for any period, with the related amount held in escrow for a defined escrow window following the closing date of the PanTHERA Transaction.

- Analyst inference. The combination of a loss-to-profit swing on both the quarter and the half-year, paired with management's stated pivot toward higher-margin recurring revenue and the discontinued-operations treatment of SAVSU, is consistent with a portfolio being reshaped rather than with a steady-state franchise; readers should treat that inference as conditional on the next filing, because the catalog does not support a causal statement of its own.

- Counter-evidence and unknowns. The filing evidence does not attribute the swing to any single cause. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension, so any segment narrative would be unsupported.

- Metrics to watch next period. Diluted earnings per share and Net Income (Loss) Attributable to Parent for both the quarter and the six-month year-to-date window, Operating Income (Loss) for the same windows, the cash-flow lines for investing, financing and operating activities against their prior-year comparatives, payments to acquire property, plant, and equipment, and the accretion line on investments. Any change in the probability assessment for the PanTHERA earnout, or in escrow treatment, would also be material to track, alongside any update on the cell-processing revenue mix management cited as its strategic focus.